MOHAN HITS LIST REGISTRATION
Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. I look forward to partnering closely with the clinical development and product strategy teams, and further supporting the Company’s mission to discover and develop life-changing ADCs for patients fighting cancer,” said Dr. “I am delighted to join the Mersana team at such an exciting point in the Company’s lifecycle, as we seek to bring UpRi to ovarian cancer patients in desperate need of new therapeutic options and advance our exciting ADC pipeline. As Mersana’s diversified first-in-class pipeline grows, Brian will continue to ensure Mersana has the resources, partnerships and infrastructure to deliver against our goals.”
MOHAN HITS LIST UPGRADE
“I would like to thank Brian for his leadership of the Product Strategy function at Mersana and his contributions towards building UpRi into a foundational medicine for ovarian cancer with the UPLIFT, UP-NEXT, and UPGRADE studies. We are delighted to have Mohan join the Mersana team and welcome his valuable insight as we continue to advance the clinical development of UpRi toward commercialization in ovarian cancer and build out our maturing pipeline of innovative ADC candidates,” commented Anna Protopapas, President and CEO of Mersana. Mohan has overseen the advancement of products through early, mid and late-stage clinical development and has helped launch 7 oncology products globally. “With over 20 years of clinical development and commercialization experience, Mohan is a seasoned biopharmaceutical executive who brings a deep expertise in overall asset strategy and program management to the Mersana team. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana’s principal financial officer. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer.
(Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. 25, 2021 (GLOBE NEWSWIRE) - Mersana Therapeutics, Inc. Brian DeSchuytner named SVP and Chief Financial OfficerĬAMBRIDGE, Mass., Oct.
0 kommentar(er)
